Dr. Feinstein has been performing research studies for various dermatology diagnoses. Contact us or check back regarding our current studies. Please see below for past studies.
Journal of Allergy and Clinical Immunology (JACI)
Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4Ra, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)
- An open-label, single-arm study to assess the safety and efficacy of Lebrikizumab in adolescent patients with Moderate to Severe Atopic Dermatitis.
- A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Subjects with Moderate to Severe Atopic Dermatitis.
- A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose Ranging Study to Evaluate the efficacy and safety of XXXXX in Adult Subjects with Moderate-to Severe Atopic Dermatitis
- An open-label, Single-arm Study to assess the safety and efficacy of: XXXXXXXX in Adolescent Patients with Moderate to Severe Atopic Dermatitis.
- A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Study of the efficacy, safety, Pharmacokinetics and Pharmacodynamics of XXX-XXX in Adult Subjects with Moderate to Severe Atopic Dermatitis.
- A 5-year Longitudinal Observational Study of Patient undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions.
- A Multicenter, Randomized, Phase II, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Evaluate the safety and efficacy of XXXXX Cream in Adolescents and Adults with Mild to Moderate Atopic Dermatitis.
- Phase IV-a Five Year Longitudinal Observational Study of Adults and Children Patients undergoing Therapy for Atopic Dermatitis.
- This is a Phase III, Randomized, Double-Blind, Placebo-controlled, Parallel group, Multisite Study to evaluate the therapeutic equivalence of generic Calcipotriene Betamethasone Dipropionate Topical Suspension, 0.005%/0.064% of Glenmark Pharmaceuticals Ltd. to that of the marketed product in the treatment of Scalp Psoriasis.
- Phase II, Safety, and Pharmacokinetic Profiles of XXXXXXXX administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis.
- A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter study to evaluate the efficacy and safety profile of XXXXXXX and XXXXXXX in subjects with Moderate to Severe Alopecia.
- Phase III, Randomized Double-Blind Study on the benefit of XXXXXXXXX for treating acne of the Adult Woman.
- A Randomized, Double-Blind, Parallel group, Placebo controlled Clinical Study of the efficacy and safety of three different daily dosages of XXXXXXX administered orally to Subjects with Active Mild to Moderate Chronic Plaque Psoriasis.
- A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-controlled Study of the safety and efficacy of XXXXXX Lotion in the treatment of Acne Vulgaris for 12 Weeks.
- A Phase II-the specific aim of the Study is to compare the safety and efficacy of a single administration of XXXXXXXXXX for Injection versus Placebo for managing Plantar Fasciitis.
- This is a Randomized, Double-Blind, Placebo controlled, Parallel group study to confirm the efficacy and safety of XXXXXXXXXX Monotherapy in Adults with Moderate-to- Severe Atopic Dermatitis (AD).
- Phase II, a Multicenter, Randomized, Double-Blind, Vehicle-controlled, Parallel Group comparison Study to evaluate the safety and efficacy of XXX-XXX cream 1% when applied twice daily for 12 weeks in Subjects with Facial Acne Vulgaris.
- A Phase II study to find out if the drug XXXXXXX Phosphate Cream is safe and has beneficial effects in people who have Alopecia Areata (partial or complete hair loss) when applied to the skin.
- A Multicenter Double-Blind, Randomized Controlled Study of XXXXXXXXX and XXXXXXXX in combination or as Monotherapy in Subjects with Psoriatic Arthritis.
- A Phase III Prospective, Single-Blinded, Randomized-controlled Trial of Micronized XXXXXXX
Injection as compared to the Saline Placebo injection in the treatment of Plantar Fasciitis.
- A Multicenter, Randomized, Double-Blind, Parallel Group, Comparative Study of XXX XXX versus XXXX for the prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster-associated pain.
- A Phase II, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
- A Randomized, Double-Blind, Placebo-controlled, Dose Ranging Phase II Study to Evaluate the efficacy and safety of RIST4721 in Subjects with Palmoplantar Pustulosis
- A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the efficacy, safety, tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 versus Placebo in Patients with Moderate to Severe Hidradenitis Suppurativa (HS)
- A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients with Moderate-To-Severe Atopic Dermatitis who are Candidates for Systemic Therapy
- A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages ≥ 12 Years to < 18 Years) with Atopic Dermatitis
- A Phase I Randomized, Placebo-controlled, single and multiple ascending dose trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered KT-474 in healthy adult Volunteers and Patients with Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients with Moderate-to-Severe Atopic Dermatitis.
